About Entrada Therapeutics, Inc.
https://www.entradatx.comEntrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs.
CEO
Dipal Doshi
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 69
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:4.87M
Value:$51.48M
MPM ASSET MANAGEMENT LLC
Shares:4.38M
Value:$46.35M
5AM VENTURE MANAGEMENT, LLC
Shares:4.26M
Value:$45.03M
Summary
Showing Top 3 of 122
About Entrada Therapeutics, Inc.
https://www.entradatx.comEntrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $1.61M ▼ | $10.3M ▼ | $-44.13M ▼ | -2.73K% ▼ | $-1.06 ▼ | $-42.25M ▲ |
| Q2-2025 | $1.95M ▼ | $48.8M ▲ | $-43.1M ▼ | -2.21K% ▼ | $-1.04 ▼ | $-45.81M ▼ |
| Q1-2025 | $20.56M ▼ | $42.35M ▼ | $-17.35M ▼ | -84.39% ▼ | $-0.42 ▼ | $-20.84M ▼ |
| Q4-2024 | $37.4M ▲ | $43.27M ▲ | $1.13M ▲ | 3.02% ▲ | $0.03 ▲ | $-4.88M ▲ |
| Q3-2024 | $19.57M | $41.23M | $-14.03M | -71.7% | $-0.35 | $-20.72M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $326.84M ▼ | $412.9M ▼ | $72.18M ▲ | $340.72M ▼ |
| Q2-2025 | $354.01M ▼ | $448.78M ▼ | $69.28M ▲ | $379.5M ▼ |
| Q1-2025 | $382.51M ▼ | $486.48M ▼ | $69.22M ▼ | $417.26M ▼ |
| Q4-2024 | $420M ▼ | $526.32M ▼ | $97.64M ▼ | $428.68M ▲ |
| Q3-2024 | $449.34M | $554.59M | $132.14M | $422.45M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-44.13M ▼ | $-28.31M ▲ | $49.11M ▲ | $8K ▼ | $20.8M ▲ | $-28.14M ▲ |
| Q2-2025 | $-43.1M ▼ | $-29.49M ▲ | $33.8M ▲ | $337K ▼ | $4.64M ▲ | $-29.76M ▲ |
| Q1-2025 | $-17.35M ▼ | $-38.51M ▼ | $4.78M ▼ | $350K ▼ | $-33.37M ▼ | $-39.65M ▼ |
| Q4-2024 | $1.13M ▲ | $-31.61M ▼ | $53.37M ▲ | $1.4M ▲ | $23.16M ▲ | $-32.24M ▼ |
| Q3-2024 | $-14.03M | $-24.27M | $-82.93M | $-11K | $-107.2M | $-24.91M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 License | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
Dipal Doshi
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 69
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 1 of 1
Price Target
Institutional Ownership
BAKER BROS. ADVISORS LP
Shares:4.87M
Value:$51.48M
MPM ASSET MANAGEMENT LLC
Shares:4.38M
Value:$46.35M
5AM VENTURE MANAGEMENT, LLC
Shares:4.26M
Value:$45.03M
Summary
Showing Top 3 of 122